当前位置:
USFDA grants tentative approval to Lupin’s generic formulation for type 2 diabetes
时间:2024-06-02 05:38:50 阅读(143)
USFDA grants tentative approval to Lupin’s generic formulation for type 2 diabetes
Global pharma major Lupin Limited on Friday announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Saxagliptin Tablets, 5 mg/5 mg and 10 mg/5 mg.
According to the company’s press statement, the approval has been granted to market a generic equivalent of Qtern Tablets, 5 mg/5 mg and 10 mg/5 mg of AstraZeneca AB. This product will be manufactured at Lupin’s Pithampur facility in India.
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT November 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- Global Markets- Stock, bonds stung by hawkish central banks
- Petrol and Diesel Rate Today, 16 March- Fuel prices unchanged; Check rates in Delhi, Mumbai, other cities
- Petrol and Diesel Rate Today, 29 March- Fuel prices unchanged; Check rates in Delhi, Mumbai, other cities
- Yatra Online gets Sebi’s nod to float IPO
- GoKwik network data report- What India shopped from D2C brands in 2023-
- Gold Price Today, 19 April- Gold trades flat as experts suggest Fed should hike rates further
- Will Nifty trade above 21,700 levels or fall ahead- See GIFT Nifty, FII data, F&O ban, crude, more before market opens
- Zee Entertainment Enterprises Rating- Add - ICC rights deal fraught with risks
- Wipro Q4FY23 net profit falls to Rs 3,149 crore, revenue at Rs 23,190 crore; Rs 12,000 crore buyback approved